Short Interest Don’t Lie: SIGA TECH INCORPORATED (OTCMKTS:SIGA) Reports Increase in Sellers; Strong Momentum for Short Players

November 16, 2016 - By Louis Casey   ·   0 Comments

Short Interest Don't Lie: SIGA TECH INCORPORATED (OTCMKTS:SIGA) Reports Increase in Sellers; Strong Momentum for Short Players

The stock of SIGA TECH INCORPORATED (OTCMKTS:SIGA) registered an increase of 6.41% in short interest. SIGA’s total short interest was 401,800 shares in November as published by FINRA. Its up 6.41% from 377,600 shares, reported previously. With 74,200 shares average volume, it will take short sellers 5 days to cover their SIGA’s short positions. The stock decreased 3.97% or $0.1 on November 15, hitting $2.42. About 12,345 shares traded hands. SIGA Technologies, Inc. (OTCMKTS:SIGA) has risen 118.02% since April 14, 2016 and is uptrending. It has outperformed by 113.33% the S&P500.

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The company has a market cap of $131.37 million. The Company’s lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. It currently has negative earnings. Tecovirimat is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

SIGA Company Profile

SIGA Technologies, Inc. (SIGA), incorporated on December 28, 1995, is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. Tecovirimat is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). Tecovirimat is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication.

Another recent and important SIGA Technologies, Inc. (OTCMKTS:SIGA) news was published by Law360.com which published an article titled: “Lessons From SIGA Technologies V. PharmAthene” on October 08, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>